Dose-Ranging Study to Evaluate Efficacy and Safety of Weekly CJC-1134-PC in Patients With T2DM on Metformin Monotherapy

NCT01514149 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

73

Enrollment

INDUSTRY

Sponsor class

Stopped Business decision

Conditions

Type 2 Diabetes Mellitus (T2DM)

Interventions

DRUG: CJC-1134-PC Injection
DRUG: Weekly placebo for CJC-1134-PC Injection

Sponsor

ConjuChem